690P Ifinatamab deruxtecan (I-DXd; DS-7300) in patients with advanced solid tumors: Updated clinical and biomarker results from a phase I/II study

医学 生物标志物 肿瘤科 内科学 癌症研究 遗传学 生物
作者
Manish R. Patel,Toshihiko Doi,T. Koyama,Gerald S. Falchook,Claire F. Friedman,Sarina A. Piha‐Paul,Martin Gutierrez,Mark M. Awad,Ahmad Mattour,Toshihiko Satoh,Norihiro Okamoto,Jasveer Singh,N. Yoshizuka,Meng Qian,Xiaozhong Qian,Brittany P. Tran,O. Dosunmu,Lu Wang,Melissa L. Johnson
出处
期刊:Annals of Oncology [Elsevier BV]
卷期号:34: S481-S482 被引量:3
标识
DOI:10.1016/j.annonc.2023.09.1876
摘要

I-DXd is a novel B7-H3–directed antibody–drug conjugate that leverages the clinically validated deruxtecan (DXd) technology with a plasma-stable linker and potent topoisomerase I inhibitor payload. Here we present a follow-up analysis (7 mo since last report) of an ongoing phase 1/2 trial that includes heavily pretreated patients with castration-resistant prostate cancer (CRPC), esophageal squamous cell carcinoma (ESCC), squamous non-small cell lung cancer (sqNSCLC), and small cell lung cancer (SCLC). DOR, OS, and B7-H3 correlations with response are reported for the first time for CRPC, ESCC, and sqNSCLC. Efficacy and safety were analyzed in patients treated with I-DXd at 4.8 to 16.0 mg/kg. Response was evaluated in patients with ≥2 postbaseline scans or discontinuation for any reason. Fourteen patients with CRPC lacked measurable target lesions at baseline (BL) and were excluded from ORR analysis. B7-H3 level was evaluated retrospectively as patients were not pre-selected by BL expression. As of 31 Jan 2023, 8 patients remained on treatment. Safety data were consistent with previous reports. I-DXd still demonstrated promising ORR results, including in an updated sample size for sqNSCLC (Table). Even in this heavily pretreated population, I-DXd exhibited durable response and encouraging early OS (Table), although further follow-up is needed. B7-H3 expression was moderate to high in most patients; no correlation was observed between response and B7-H3 level, and an update will be presented at the congress.Table: 690PEfficacyCRPCESCCsqNSCLCSCLCNo. of prior lines, median (range)6 (1 – 11)4 (1 – 7)3 (1 – 12)2 (1 – 9)ORR by RECIST v1.1 (confirmed) n (%)n = 59 15 (25)n = 28 6 (21)n = 13 4 (31)n = 21 11 (52)DOR by RECIST v1.1 Median, mo (95% CI)n = 59 6.4 (2.8 – 10.6)n = 28 3.5 (2.4 – NE)n = 13 4.1 (2.8 – NE)n = 21 5.9 (2.8 – 7.5)PFS by RECIST v1.1 Median, mo (95% CI)n = 73 4.8 (3.9 – 5.9)n = 28 2.8 (1.6 – 4.2)NRn = 21 5.8 (3.9 – 8.1)OS Median, mo (95% CI)n = 73 13.5 (10.3 – 16.6)n = 28 7.0 (4.8 – 12.2)NRn = 21 9.9 (5.8 – NE)DOR, duration of response; NE, not estimable; NR, not reported; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; RECIST, Response Evaluation Criteria In Solid Tumors. Open table in a new tab DOR, duration of response; NE, not estimable; NR, not reported; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; RECIST, Response Evaluation Criteria In Solid Tumors. I-DXd continues to demonstrate a manageable safety profile and promising antitumor activity with encouraging DOR and OS in these heavily pretreated patients, which warrants further clinical evaluation across multiple indications.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
盈缺完成签到,获得积分10
刚刚
刚刚
1秒前
1秒前
深情安青的应助被木田采纳,获得10
1秒前
pyb0919发布了新的文献求助10
1秒前
侯赛因发布了新的文献求助10
2秒前
科研通AI6.3的应助被我爱学习采纳,获得10
2秒前
aw发布了新的文献求助10
3秒前
4秒前
4秒前
5秒前
小聋包完成签到,获得积分10
5秒前
6秒前
Rongxing完成签到 ,获得积分10
6秒前
6秒前
7秒前
小蘑菇的应助被xucc采纳,获得10
7秒前
理想完成签到,获得积分10
8秒前
8秒前
8秒前
9秒前
GamAooL发布了新的文献求助10
10秒前
10秒前
啦啦啦完成签到 ,获得积分10
11秒前
Iriss完成签到 ,获得积分10
11秒前
11秒前
行走的荷尔蒙的应助被依山尽采纳,获得30
12秒前
ZYP完成签到,获得积分10
12秒前
科目三的应助被小棕瓶采纳,获得10
12秒前
revo完成签到,获得积分10
13秒前
温暖大米完成签到,获得积分20
13秒前
酷炫的金鱼完成签到 ,获得积分10
13秒前
喜悦的聪展完成签到 ,获得积分10
13秒前
典雅碧空发布了新的文献求助10
14秒前
慕青的应助被Lily采纳,获得10
14秒前
天真的乌龟完成签到 ,获得积分10
14秒前
12发布了新的文献求助10
15秒前
syvshc的应助被chenlina采纳,获得10
15秒前
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175262
求助须知:如何正确求助?哪些是违规求助? 9567017
关于积分的说明 21789663
捐赠科研通 7769695
什么是DOI,文献DOI怎么找? 3431840
关于科研通互助平台的介绍 2556124
邀请新用户注册赠送积分活动 2477241